• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Topical glaucoma agent offers real IOP reduction in study

Article

Plymouth, England—Latanoprost (Xalatan, Pfizer Ophthalmics), a potent topical ocular antihypertensive agent, does not seem to cause changes in the central corneal thickness after 2 months of follow-up. This result contradicts previous studies that reported a statistically significant decrease in the central corneal thickness, according to George D. Pappas, MD.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.